The Patient and GCT - 2021 World Medical Innovation Forum
May 2–4, 2022

The Patient and GCT

The Patient and GCT

Wednesday, May 19, 2021

8:55 AM – 9:20 AM

GCT development for rare diseases is driven by patient and patient-advocate communities. Understanding their needs and perspectives enables biomarker research, the development of value-driving clinical trial endpoints and successful clinical trials. Industry works with patient communities that help identify unmet needs and collaborate with researchers to conduct disease natural history studies that inform the development of biomarkers and trial endpoints. This panel includes patients who have received cutting-edge GCT therapy as well as caregivers and patient advocates.

Patricia Musolino, MD, PhD
  • Co-Director Pediatric Stroke and Cerebrovascular Program, MGH
  • Assistant Professor of Neurology, HMS
Jack Hogan
  • Patient, MEE
Jeanette Hogan
  • Parent of Patient, MEE
Jim Holland
  • CEO,
Barbara Lavery
  • Chief Program Officer, ACGT Foundation
Dan Tesler
  • Clinical Trial Patient, BWH/DFCC
Sarah Beth Thomas, RN
  • Professional Development Manager, BWH
  • Q&A

    09:25 AM – 09:40 AM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA